By Billy Candra 
Scientists and clinicians at the University of Nottingham and Nottingham University Hospitals NHS Trust (NUH) have achieved a monumental breakthrough in brain tumour diagnostics, developing an ultra-rapid genetic classification method that promises to dramatically cut the agonizing wait time for patients from up to eight weeks to as little as two hours. This pioneering technique, detailed in a new study published today in the prestigious journal Neuro-Oncology, represents a paradigm shift in how brain tumours are identified and treated, holding the potential to improve care for thousands of individuals across the United Kingdom each year.
The groundbreaking approach has already demonstrated a 100% success rate in a pilot phase, where it was utilised during 50 brain tumour surgeries at NUH. Crucially, the method delivered rapid, intraoperative diagnoses, providing initial diagnostic results in under two hours from the commencement of surgery, with detailed tumour classifications available within minutes of sequencing. The platform’s robust capabilities further enable a fully integrated diagnosis within 24 hours, offering an unprecedented level of speed and precision in a field where every moment counts.
The Critical Need for Speed: A Current Landscape of Anxiety and Delay
Brain tumours are among the most complex and devastating forms of cancer, with their diagnosis and subsequent treatment presenting formidable challenges. In the UK, an alarming 34 people are diagnosed with some form of brain tumour every day, translating to over 12,000 new cases annually. For the most aggressive types of brain cancer, the average survival rate can tragically be less than a year, underscoring the desperate need for rapid and accurate intervention.
The current diagnostic pathway is notoriously protracted and emotionally taxing for patients and their families. Upon the initial suspicion of a tumour, often following an MRI scan, patients undergo a series of consultations to discuss potential tumour types. The definitive diagnosis, however, hinges on complex genetic tests performed on a tumour sample obtained through surgery. These samples are typically sent to centralised analysis facilities, a process that can take anywhere from six to eight weeks, and sometimes even longer, to yield comprehensive results.
This prolonged waiting period is not merely an inconvenience; it is a source of immense trauma and anxiety for patients facing a life-altering diagnosis. The delay directly impacts treatment efficacy, as the initiation of critical therapies like radiotherapy and chemotherapy is postponed. Such delays can significantly diminish the chances of successful treatment, highlighting a critical bottleneck in the existing healthcare system. For years, clinicians have grappled with the inherent limitations of these traditional methods, which, despite their accuracy, failed to meet the urgent temporal demands of oncology.
A Journey of Innovation: From Weeks to Minutes
The journey to this revolutionary diagnostic method began with a profound understanding of these systemic challenges and a commitment to leveraging cutting-edge genetic technology. The team of experts in Nottingham, comprising specialists from both the University and NUH, set out to develop an ultra-rapid genetic diagnosis that would fundamentally eliminate these delays.
At the heart of this innovation lies the work of Professor Matt Loose, a distinguished biologist from the School of Life Sciences at the University of Nottingham. Professor Loose developed a novel method for sequencing specific parts of human DNA at a higher depth, utilising portable sequencing devices from Oxford Nanopore Technologies. This technology allows for the much faster examination of relevant sections of the human genome, enabling multiple regions of DNA to be sequenced simultaneously and thereby drastically accelerating the entire diagnostic process.
Professor Loose recounted the historical context, noting that "When we first were able to sequence an entire human genome in 2018, it took around five labs and six months to do, which obviously isn’t ideal when time is of the essence for a patient." This stark contrast illustrates the immense progress made. His subsequent research focused on refining techniques to examine relevant parts of the human genome even more quickly, paving the way for the current breakthrough.
The Nottingham team has now successfully applied this advanced sequencing method to genetically test brain tumour samples. Their innovation culminates in ROBIN, a sophisticated software tool that operates in conjunction with P2 PromethION nanopore sequencers. ROBIN sequences DNA by detecting minute changes in electrical current flow as single molecules of DNA pass through a nanopore – a tiny, protein-based hole embedded in a membrane. This intricate process allows for the rapid and precise identification of genetic markers crucial for tumour classification.
"This new method now allows us to choose the bits of DNA that we need to look at in order to answer specific questions, such as what type of tumour and how can it be treated," Professor Loose explained. "Combined with our later research where we were able to look at relevant parts of the human genome more quickly – then we now have a process where we can use ROBIN to create comprehensive classifications of tumours more quickly."
The diagnostic process, following the surgical removal of a tumour sample, involves sending it to the pathology lab for DNA extraction. This extracted DNA is then promptly sent to Professor Loose’s team for sequencing. A key focus early in the process is the analysis of methylation patterns, which Professor Loose highlights as crucial for defining the tumour type. "Once we have a sample from a patient, we can now quickly extract the DNA and look at the different properties to give us the information we need. Methylation is the one we are most interested in early on in this instance because that defines the tumour type," he added.
Transformative Clinical Impact and Expert Endorsement
The immediate clinical benefits of this ultra-rapid diagnostic method are profound and far-reaching. Dr. Stuart Smith, a Neurosurgeon from the School of Medicine at the University and within NUH, emphasized the dramatic shift from previous practices. "Traditionally, the process of diagnosing brain tumours has been slow and expensive. Now, with this new technology, we can do more for patients because we can get answers so much more quickly, which will have a much bigger influence on clinical decision making, in as little as two hours," he stated.
Dr. Smith highlighted the severe emotional toll the waiting period takes on patients. "Patients find waiting many weeks for results extremely difficult, and this adds to the anxiety and worry at what is already a very difficult time." He also pointed to the unprecedented possibility of informing surgical strategy in real-time. "This type of operation can be quite long, so potentially, a surgeon could be informed during surgery of the accurate diagnosis, which would then impact on the surgical strategy." This intraoperative diagnostic capability is a game-changer, allowing surgeons to adapt their approach based on the tumour’s precise genetic makeup, potentially leading to more targeted and effective resections.
Further endorsing the innovation, Dr. Simon Paine, a Consultant Neuropathologist at NUH, declared, "This new method of diagnosing brain tumours is going to be a game changer; it really is revolutionary. It not only increases the speed at which the results will be available, but the degree of accuracy of the diagnosis as well is incredible." The improved accuracy is as vital as the speed, as precise genetic classification is increasingly critical for guiding personalized treatment plans, including the selection of specific chemotherapies or targeted molecular therapies that are most likely to be effective against a particular tumour subtype.
Broader Implications: Cost-Effectiveness, Equity, and Future Horizons
Beyond the immediate clinical benefits of speed and accuracy, the Nottingham team’s breakthrough carries significant broader implications for healthcare policy, patient access, and the economic landscape of diagnostics. One of the most compelling aspects of this new method is its cost-effectiveness. Professor Loose revealed, "Not only is the test more accurate and quicker, but it is also cheaper than current methods. Our calculations stand at around £450 per person, potentially less when scaled-up."
This cost reduction stems from the method’s ability to consolidate multiple traditional tests into a single, comprehensive analysis. "There are a few reasons for this. Our method can eliminate the need for four to five separate tests, reducing costs as a consequence as we are getting more information from the single test we do. Most importantly, it delivers results to the patients when they need them," Professor Loose explained. This economic advantage could be pivotal in facilitating widespread adoption across the National Health Service (NHS).
The Brain Tumour Charity, a leading patient advocacy organisation, has lauded the innovation. Dr. Simon Newman, Chief Scientific Officer at The Brain Tumour Charity, underscored the profound impact on patients: "The delivery of an accurate diagnosis within hours of surgery will be transformative for all patients, ensuring rapid access to the optimal standard of care and – crucially – removing the uncertainty patients face when having to wait weeks for their diagnosis and prognosis."
Dr. Newman further highlighted the potential for greater equity in healthcare access: "The potential to combine so many separate tests into one and deliver at a localised level is a game changer for driving equity of access to rapid and accurate molecular diagnosis." This localized testing capability could decentralize diagnostics, reducing reliance on distant centralized labs and ensuring that patients, regardless of their geographical location, can benefit from prompt and precise diagnoses. The charity is actively supporting the advancement of this technology, with the BRAIN MATRIX Trial, funded by The Brain Tumour Charity, currently exploring how this technology can match patients to personalized clinical trials across the UK. This trial represents a critical step towards integrating the rapid diagnostic capabilities with targeted therapeutic interventions, paving the way for truly personalized medicine in neuro-oncology.
The Nottingham team is now actively looking to roll out this new testing method across NHS Trusts throughout the UK. Such a national implementation would not only standardize and elevate the quality of brain tumour diagnostics but also potentially free up significant resources within the NHS by streamlining the diagnostic pathway. The ripple effect could extend beyond brain tumours, with the underlying nanopore sequencing technology potentially adaptable for rapid diagnosis of other cancers or complex genetic diseases, establishing the UK as a leader in this critical area of medical innovation.
The implications for public health are substantial. Faster diagnosis means earlier treatment, which can lead to better outcomes, improved quality of life, and potentially increased survival rates for patients with aggressive brain tumours. The reduction in patient anxiety and trauma cannot be overstated, offering a beacon of hope in what is inherently a dark and challenging journey. This breakthrough is not just a scientific achievement; it is a profound human one, promising to transform the experience of thousands facing a brain tumour diagnosis each year. The collaboration between the University of Nottingham and Nottingham University Hospitals NHS Trust stands as a testament to the power of interdisciplinary research and clinical application in driving forward medical progress for the benefit of all.